Feng Yu / Shutterstock.com
Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review (IPR) petition challenging a patent owned by German pharmaceutical company Bayer.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bayer, Fustibal, Stivarga, PTAB, patent, IPR, inter partes review